Improving Diagnosis for Lewy Body Dementia
In partnership with the Alzheimer’s Association, The Michael J. Fox Foundation for Parkinson’s Research, and the American Academy of Neurology, the American Brain Foundation is seeking to accelerate progress in the diagnosis of Lewy body dementia (LBD). LBD is the most common form of dementia after Alzheimer’s disease.
Currently, LBD can only be definitively diagnosed with a brain autopsy after death. As a result of a delay in diagnosis and misdiagnosis, people with LBD and their caregivers endure daily challenges and uncertainty. The goal of the 2022 Cure One, Cure Many Award is to attract the best minds in brain disease research to find a biomarker (diagnostic test) for LBD.
Proposals for the award will be reviewed by a panel of preeminent scientists, and can address disorders across the LBD spectrum. The American Brain Foundation seeks applications aimed for discovery, validation, and acceleration of LBD-related biomarkers. Projects should specifically have the potential to identify one or more biomarkers that will support or confirm that Lewy body disease is the underlying cause of dementia at any stage. Applications for the 2022 Cure One, Cure Many Award will be managed by the American Academy of Neurology. Pre-proposal applications will be accepted beginning July 1, 2021. Full proposals will be accepted by invitation only and will be due on October 29, 2021. Grant winners will be selected and announced in December 2021. Award funding will begin in January 2022.